Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study.

Autor: Thomsen LCV; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway.; Norwegian Institute of Public Health, 5015 Bergen, Norway., Kleinmanns K; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway., Anandan S; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway., Gullaksen SE; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway., Abdelaal T; Delft Bioinformatics Laboratory, Delft University of Technology, 2628XE Delft, The Netherlands.; Department of Radiology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands., Iversen GA; Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway., Akslen LA; Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.; Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway., McCormack E; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.; Centre for Pharmacy, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway., Bjørge L; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway.

Publikováno v: Cancers [Cancers (Basel)] 2023 Oct 23; Vol. 15 (20). Date of Electronic Publication: 2023 Oct 23.

HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.

Autor: Aasbø G; Department of Research, Cancer Registry of Norway, Oslo, Norway. gunvor.aasbo@medisin.uio.no.; Department of Interdisciplinary Health Sciences, Institute of Health and Society, University of Oslo, Oslo, Norway. gunvor.aasbo@medisin.uio.no., Tropè A; Section for Cervical Cancer Screening, Cancer Registry of Norway, Oslo, Norway., Nygård M; Department of Research, Cancer Registry of Norway, Oslo, Norway., Christiansen IK; National HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway., Baasland I; Section for Cervical Cancer Screening, Cancer Registry of Norway, Oslo, Norway.; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway., Iversen GA; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway., Munk AC; Department of Obstetrics and Gynaecology, Sørlandet Hospital Kristiansand, Kristiansand, Norway., Christiansen MH; Department of Obstetrics and Gynaecology, Stavanger University Hospital, Stavanger, Norway., Presthus GK; National HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway., Undem K; Department of Research, Cancer Registry of Norway, Oslo, Norway.; National Institute of Occupational Health, Oslo, Norway., Bjørge T; Section for Cervical Cancer Screening, Cancer Registry of Norway, Oslo, Norway.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway., Castle PE; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.; Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA., Hansen BT; Department of Research, Cancer Registry of Norway, Oslo, Norway.; Department of Infection Control and Vaccine, Norwegian Institute of Public Health, Oslo, Norway.

Publikováno v: British journal of cancer [Br J Cancer] 2022 Nov; Vol. 127 (10), pp. 1816-1826. Date of Electronic Publication: 2022 Aug 23.

A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway.

Autor: Vistad I; Department of Obstetrics and Gynecology, Sørlandet Hospital, Kristiansand, Norway., Bjørge L; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.; Departments of Global Public Health and Primary Care and Clinical Medicine, Haukeland University Hospital, Bergen, Norway.; Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway., Solheim O; Department of Gynecologic Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway., Fiane B; Department of Obstetrics and Gynecology, Stavanger University Hospital, Stavanger, Norway., Sachse K; Department of Obstetrics and Gynecology, Akershus University Hospital, Lørenskog, Norway., Tjugum J; Department of Obstetrics and Gynecology, Førde Central Hospital, Førde, Norway., Skrøppa S; Department of Obstetrics and Gynecology, Vestfold Hospital Trust, Tønsberg, Norway., Bentzen AG; Department of Gynecologic Oncology, University Hospital of Tromsø, Tromsø, Norway., Stokstad T; Department of Obstetrics and Gynecology, St. Olav's University Hospital, Trondheim, Norway., Iversen GA; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway., Salvesen HB; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway., Kristensen GB; Department of Gynecologic Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Dørum A; Department of Gynecologic Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.

Publikováno v: Acta obstetricia et gynecologica Scandinavica [Acta Obstet Gynecol Scand] 2017 Oct; Vol. 96 (10), pp. 1162-1169.